Age at onset of genetic (E200K) and sporadic Creutzfeldt-Jakob diseases is modulated by the CYP4X1 gene. Issue 12 (21st July 2018)

• Record Type: Journal Article
• Authors: Poleggi, Anna; van der Lee, Sven; Capellari, Sabina; Puopolo, Maria; Ladogana, Anna; De Pascali, Eleonora; Lia, Debora; Formato, Alessia; Bartoletti-Stella, Anna; Parchi, Piero; van Duijn, Cornelia; Pocchiari, Maurizio
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 89:Issue 12(2018)
• Page Start: 1243
• Page End: 1249
• Publication Date: 2018-07-21
• Subjects: Creutzfeldt-Jakob disease -- GWA study; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2018-318756
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objectives: The Glu to Lys change at codon 200 (E200K) of the PRNP gene is the most frequent mutation associated to genetic Creutzfeldt-Jakob disease (CJD) and the only one responsible for geographical clusters. Patients carrying this mutation develop disease at different ages and show variable clinical phenotypes that are not affected by the methione/valine polymorphism at codon 129 of the PRNP gene suggesting the influence of other factors. The objective of this study is to look for genes other than PRNP that might be responsible of this variability. Methods: We searched for other genes by performing genome-wide analyses (GWA) on 19 patients with genetic CJD and 18 healthy subjects carrying the E200K mutation of PRNP and belonging to the Calabrian cluster in Italy. We then validate this result in 32 patients with E200K CJD from non-cluster areas and 259 patients with sporadic CJD referred to the Italian CJD national registry. Results and conclusions: We identified two single nucleotide polymorphisms on the CYP4X1 gene locus as candidate disease modifiers in patients with E200K CJD of the cluster area and confirmed this finding in 32 patients with E200K CJD from non-cluster areas and 259 patients with sporadic CJD. Our results indicate that the CYP4X1 gene modulates the onset of disease in patients with E200K genetic and sporadic CJD. This finding improves our understanding on the pathogenesis of CJD, suggests new targets for developing novel therapeutic strategies and might be useful for the stratification of patients in future preventive treatment trials.